Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance

被引:198
作者
Hung, J
McQuillan, BM
Chapman, CML
Thompson, PL
Beilby, JP
机构
[1] Univ Western Australia, Heart Res Inst Western Australia, Perth, WA 6009, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[3] Univ Western Australia, Sch Surg & Pathol, Perth, WA 6009, Australia
[4] Univ Western Australia, Western Australia Ctr Pathol & Med Res PathCtr, Perth, WA 6009, Australia
关键词
IL-18; metabolic syndrome; obesity; insulin resistance; inflammatory mediators;
D O I
10.1161/01.ATV.0000163843.70369.12
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - Activated innate immunity is thought to be involved in the pathogenesis of metabolic syndrome and type 2 diabetes. Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine with important regulatory functions in the innate immune response. We sought to determine whether an elevated IL-18 concentration was a risk predictor for metabolic syndrome in a community population independent of obesity and hyperinsulinemia. Methods and Results - A representative general population, aged 27 to 77 years, without clinical diabetes was studied for clinical and biochemical risk factors for metabolic syndrome. Serum IL-18 concentration measured in 955 subjects correlated with metabolic syndrome traits including body mass index (BMI), waist circumference, triglyceride, high-density lipoprotein ( inversely), and fasting glucose and insulin levels ( all P < 0.001). Mean IL-18 levels rose progressively with the increasing number of metabolic risk factors ( ANOVA P <0.001). After adjusting for age, gender, BMI, and insulin levels, increasing IL-18 tertiles were associated with an odds ratio for metabolic syndrome of 1.0, 1.42, and 2.28, respectively ( P trend = 0.007). The graded risk relation was even stronger in nonobese subjects and not attenuated when adjusted for C-reactive protein and IL-6 levels. Conclusion - Our findings support the hypothesis that activation of IL-18 is involved in the pathogenesis of the metabolic syndrome.
引用
收藏
页码:1268 / 1273
页数:6
相关论文
共 45 条
[1]   Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes [J].
Aso, Y ;
Okumura, K ;
Takebayashi, K ;
Wakabayashi, S ;
Inukai, T .
DIABETES CARE, 2003, 26 (09) :2622-2627
[2]  
Bastard JP, 1999, CIRCULATION, V99, P2221
[3]   Atherothrombosis, inflammation, and diabetes [J].
Biondi-Zoccai, GGL ;
Abbate, A ;
Liuzzo, G ;
Biasucci, LM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1071-1077
[4]   Interleukin-18 and the risk of coronary heart disease in European men -: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) [J].
Blankenberg, S ;
Luc, G ;
Ducimetière, P ;
Arveiler, D ;
Ferrières, J ;
Amouyel, P ;
Evans, A ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 108 (20) :2453-2459
[5]   Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].
Blankenberg, S ;
Tiret, L ;
Bickel, C ;
Peetz, D ;
Cambien, F ;
Meyer, J ;
Rupprecht, HJ .
CIRCULATION, 2002, 106 (01) :24-30
[6]   Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis [J].
Chapman, CML ;
Beilby, JP ;
McQuillan, BM ;
Thompson, PL ;
Hung, J .
STROKE, 2004, 35 (07) :1619-1624
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[9]   Low-grade systemic inflammation and the development of type 2 diabetes - The atherosclerosis risk in communities study [J].
Duncan, BB ;
Schmidt, MI ;
Pankow, JS ;
Ballantyne, CM ;
Couper, D ;
Vigo, A ;
Hoogeveen, R ;
Folsom, AR ;
Heiss, G .
DIABETES, 2003, 52 (07) :1799-1805
[10]   Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women [J].
Escobar-Morreale, HF ;
Villuendas, G ;
Botella-Carretero, JI ;
Sancho, J ;
San Millán, JL .
DIABETOLOGIA, 2003, 46 (05) :625-633